Effectiveness of HPV Vaccine Among Adolescents and Reproductive Women
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hpv. Basic parameters: 12 years — 45 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Thailand
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effectiveness of Single Dose or Two Doses of HPV Vaccine Among Adolescents and Reproductive Women: A Test-negative Control Study
Overview
To assess the effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among adolescents and adults. We conduct the test-negative control study including 12-45 women who interest to do a check-up pap smear. Cases were women who met the inclusion criteria and tested positive for HPV DNA, and controls were defined as women who met inclusion criteria but tested negative. For the proposed HPV VE study, we will enroll nine controls for each enrolled case. The participants will be interviewed about their demographics and vaccine histories. Potential confounders data will be collected by interview or self- report questionnaire. HPV DNA test will be done by urine or self-cervical sampling (optional). In case the participant has previous HPV test result within 1 year, the result will be recorded and analysed without repeating the test.
Primary outcome measures
- The real world effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among women aged 12-45 [Time frame: 1 visit (1 day)]
Eligibility criteria
Inclusion criteria
- Women aged 12-45 who willing to do HPV test check-up.
- Subject has provided written informed consent prior to performance of any study-specific procedures and is willing and has means to be contacted and to contact the investigator during the study.
- Based on clinical judgment, the participant with underlying chronic disease who has stable and well-controlled medical conditions.
Exclusion criteria
- Participant with history of total hysterectomy and loop electrosurgical excision procedure.
- Participant who received 3 doses HPV vaccine.
- Any condition that might confound the interpretation of vaccine effectiveness by investigator
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Thailand · 2 centers
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University — Bangkok
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi — Bangkok
Identifiers
NCT: NCT06220747 · NRCT9-3